Skip to main content
. 2019;20(2):545–548. doi: 10.31557/APJCP.2019.20.2.545

Table 3.

Cu/ Zn Ratio in All Study Groups

Tumor Type Cu/Zn
Benign: PA (16) 1.03±0.3
Malignant: MEC (18) 1.5±1. 8
ADCC (10) 1 ±0.4
ACC (4) 1.1±0.4
SCC (4) 1.03±0.6
Malignant mixed tumor (8) 0.8 ±0.4
Control (28)- 1.1±0.3

PA, pleomorphic adenoma; MEC, mucoepidermoid carcinoma; ADCC, adenoid cystic carcinoma; ACC, acinic cell carcinoma; SCC, Squamous cell carcinoma